Results

1–6 of 6 results for Mark R. Barakat

Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Updates from the Field
2021
One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO
Mark R. Barakat, MD
Updates from the Field
2020
Uncertain Benefit of Vitrectomy for Post-Injection Endophthalmitis in Age-Related Macular Degeneration
Mark R. Barakat, MD
On Demand Cases, Courses, and Papers
2017
Transitioning Vitreoretinal Surgery From Microscope to Stereoscopic Display
Mark R. Barakat, MD
Updates from the Field
2016